| EDUCATION |
|
Residency:
Specialized Ambulatory Care Residency, Department of Family
Practice, University of Iowa, 1995. |
|
Doctor of
Pharmacy: University of Iowa, College of Pharmacy, 1994. |
|
Bachelor
of Science: University of Iowa, College of Pharmacy, 1992.
|
| Professional
Experience |
|
Research Director,
Northeast Iowa Medical Education Foundation, Waterloo,
IA, 2004-present. |
|
Associate Research
Director, Northeast Iowa Medical Education Foundation,
Waterloo, IA, 2003-2004. |
|
Assistant Professor (Clinical)
University of Iowa, College of Pharmacy, 1995-present. |
|
Clinical Pharmacy Faculty Northeast
Iowa Family Practice Center, Waterloo, IA, 1995-present. |
|
Clinical Research Liaison Northeast
Iowa Medical Education Foundation, Waterloo, IA, 1995-present. |
|
Clinical Pharmacist-Volunteer
Cedar Valley Hospice, Waterloo, IA, 1996-present. |
|
Staff Pharmacist: VA Medical
Center, Iowa City, IA, 1992-1995. |
|
Research Assistant University
of Iowa, College of Pharmacy (D. Geraets, Pharm.D.),
1993-1994. |
|
Research Assistant: University
of Iowa, College of Medicine, (G.F. Gebhart, Ph.D.),
1991-1992. |
| Honors and Awards
|
|
North
American Menopause Society – Pfizer Reporter
Award, 2000. |
|
Faculty
Teacher of the Year Award – Northeast Iowa Family
Practice Center, 1999. |
|
Meritorious
Service Award – Northeast Iowa Family Practice
Center, 1998. |
|
Who's
Who in Medicine and Healthcare, 1998. |
|
Tri-State
New Practitioner Leadership Conference - participant,
1997. |
|
Sandoz Pharm.D. Award,
1994. |
|
Iowa Pharmacy Foundation Scholarship, 1991. |
|
Rena Fee Welch Scholarship,
1988-1989. |
|
Dean's list, 1990-1992. |
| ORganizational
Membership |
|
American Association
of Colleges of Pharmacy |
|
American College of Clinical Pharmacy member: Cardiology Practice & Research
Network, Ambulatory Care Practice & Research
Network |
|
Society of Teachers of Family Medicine member: Women's Health Practice & Research
Network, Group on Pharmacotherapy |
|
North American Primary
Care Research Group |
|
American Society of
Health-System Pharmacists |
|
Iowa Pharmacists Association, House of Delegates 1999, At-Large Trustee (elected) 2005 |
|
| Select Scholarly
Activities |
|
A
randomized, double-blind, parallel-group, multicenter
study to compare clinical health outcomes of telithromycin
versus azithromycin in outpatients with community acquired
lower respiratory tract infections. Sponsor: Aventis, Sub-investigator, Northeast Iowa Family Practice Center, 2005. |
|
A
double-blind, long-term evaluation of the safety of
topically applied ketoprofen transfersome gel in comparison
to oral naproxen for the treatment of pain associated
with osteoarthritis of the knee. Sponsor: McNeil, Sub-investigator, Northeast Iowa Family Practice Center, 2005. |
|
A
prospective observational study for the psychometric
validation of a patient-reported questionnaire in acute
exacerbations of chronic obstructive pulmonary disease. Sponsor: GlaxoSmithKline,
Sub-investigator, Northeast Iowa Family Practice Center, 2005. |
|
Patient
preference of dosing with postmenopausal osteoporosis
treated with once-monthly ibandronate and once-weekly
alendronate. A six month, two sequence, two
period crossover study.
Sponsor: Roche, Sub-investigator,
Northeast Iowa Family Practice Center, 2004. |
|
Improving
adherence to blood pressure guidelines. Sponsor: National
Institutes of Health, Sub-investigator,
Northeast Iowa Family Practice Center, 2004. |
|
A
prospective, multinational, multicenter, double-blind,
randomized, active-controlled trial to compare the
effects of Lotrel to benazepril and hydrochlorothiazide
combined in the reduction of cardiovascular morbidity
and mortality in patients with high risk hypertension
(ACCOMPLISH study)
Sponsor: Novartis, Sub-investigator,
Northeast Iowa Family Practice Center, 2004. |
|
A
multicenter, double-blind, randomized, parallel-group
study to compare the effect of 24 weeks treatment with
LAF237 (50mg QD or BID) or placebo as add-on therapy
in patients with type 2 diabetes inadequately controlled
with glimepiride monotherapy. Sponsor: Novartis, Sub-investigator,
Northeast Iowa Family Practice Center, 2004. |
|
A
24-week randomized, double-blind, multi-center, active-controlled
(pioglitazone) study to evaluate the efficacy, safety,
and tolerability of tesiglitazar therapy when administered
to patients with type 2 diabetes (GALLANT 6). Sponsor: AstraZeneca, Sub-investigator,
Northeast Iowa Family Practice Center, 2004. |
|
A
randomized, parallel-design, multi-center study to
evaluate the efficacy of avinza vs. oxycontin for the
treatment of chronic low back pain. (#178900). Sponsor: Organon, Sub-investigator,
Northeast Iowa Family Practice Center, 2004. |
|
Prevention regimen for effectively
avoiding second strokes (PROFESS): a double-blind,
active and placebo controlled study of Aggrenox vs. clopidogrel,
with and without Micardis. Sponsor: Boehringer
Ingelheim Pharmaceuticals, Inc., Sub-investigator, Northeast Iowa Family Practice Center, 2003. |
|
Limited
access protocol for the use of cisapride in the treatment
of refractory gastroesophageal
reflux disease and other gastrointestinal motility
disorders. (CIS-USA-154). Sponsor: Janssen Pharmaceutica, Co-investigator,
Northeast Iowa Family Practice Center, 2002. |
|
Clinical
utility of amlodipine/atorvastatin to improve concomitant
cardiovascular risk factors
of hypertension and dyslipidemia. (GEMINI). Sponsor: Pfizer, Sub-investigator,
Northeast Iowa Family Practice Center, 2002. |
|
A
multicenter, randomized, comparative study to evaluate
the efficacy and safety of levofloxacin
in the treatment of children who have recurrent and/or
persistent acute otits media. Sponsor: Johnson & Johnson, Sub-investigator,
Northeast Iowa Family Practice Center, 2002. |
|
Phase
IIb parallel group, placebo controlled study of two
different maintenance doses of orally
administered microencapsulated ragweed pollen extract. Sponsor: Allergenics, Inc., Sub-investigator, Northeast Iowa Family Practice Center, 2002. |
|
A phase III, randomized, double-blind, placebo-controlled,
outpatient study to assess the long-term safety and
efficacy of two dose levels of a modified release
formulation of NBI-34060 in adult patients with primary
insomnia. Sponsor: Neurocrine Biosciences, Inc., Sub-investigator, Northeast Iowa Family Practice Center, 2002. |
|
An epidemiological observational
study of deep vein thrombosis. Sponsor: Aventis/Genecom, Principal Investigator, Northeast Iowa Family Practice
Center, 2002. |
|
A phase IIa comparative stdy of the safety and
efficacy of ABT-492 100mg daily, 200mg daily, 400mg
daily, and levofloxacin 500mg daily for the treatment
of subjects with acute exacerbation of chronic bronchitis. Sponsor: Abbott
Labs, Northeast
Iowa Family Practice Center, 2002. |
|
An international, multicenter,
stratified, randomized, double-blind, 52 week gastrointestinal
clinical safety study to demonstrate that COX 189 (400mg
QD) reduces the risk to develop complicated ulcers as
compared to NSAIDs (ibuprofen 800mg TID) in osteoarthritis
patients.
Sponsor: Novartis Pharmaceuticals,
Sub-investigator, Northeast Iowa Family Practice Center, 2002. |
|
A multinational, randomized, double-blind, placebo-controlled
study of efficacy and safety of long term administration
of nateglinide and valsartan in the prevention of diabetes
and cardiovascular outcomes in subjects with impaired
glucose tolerance. Sponsor: Novartis Pharmaceuticals, Co-Investigator, Northeast Iowa Family Practice Center, 2002. |
|
A multicenter, double-blind,
placebo-controlled study to compare the efficacy and
tolerability of valdecoxib vs. tramadol in the treatment
of acute ankle sprains. Sponsor: Pharmacia,
Sub-investigator, Northeast Iowa Family Practice Center, 2002. |
|
Impact of resistance on the clinical outcome in
patients with acute uncomplicated cystitis. Sponsor: Infectious
Disease Society of Pharmacists,
Co-Investigator,
Northeast Iowa Family Practice Center, 2001. |
|
A randomized, double-blind,
comparator-controlled study of pioglitazone vs. glyburide
in the treatment of subjects with type 2 diabetes mellitus
and mild cardiac disease (520). Sponsor: Takeda
Pharmaceuticals, Sub-investigator, Northeast Iowa Family Practice Center, 2001. |
|
A double-blind, placebo-controlled, randomized
six week comparison study of the efficacy of valdecoxib
20mg QD and rofecoxib 25mg QD in relieving the signs
and symptoms of osteoarthritis of the knee. Sponsor: Pharmacia, Sub-investigator, Northeast Iowa Family Practice Center, 2001. |
|
An open-label, randomized,
rater-blinded study to compare rate of remission in patients
with major depressive disorder treated with venlafaxine
extended-release vs. selective serotonin reuptake inhibitors. Sponsor: Wyeth-Ayerst, Sub-investigator, Northeast Iowa Family Practice Center, 2001. |
|
A multicenter, double-blind,
randomized study to compare the safety and efficacy of
levofloxacin 750mg once daily for five days vs. levofloxacin
500mg once daily for ten days in the treatment of mild
to severe community acquired pneumonia in adults (CAPSS-150). Sponsor: Ortho-McNeil, Sub-investigator, Northeast Iowa Family Practice Center, 2001. |
|
A 24 week randomized, open
label study of health care resource use, quality of life,
and productivity with alosetron versus traditional therapy
in females with non-constipated irritable bowel syndrome. Sponsor: Glaxo
Wellcome, Sub-investigator, Northeast Iowa Family Practice Center, 2000. |
|
An observational study to assess
prevalence, natural history, and burden of illness of
IBS in clinical practice and to evaluate the impact of
alosetron treatment on natural history and burden of
illness in a cohort of non-constipated females with IBS.
Sponsor: Glaxo
Wellcome, Sub-investigator, Northeast Iowa Family Practice Center, 2000. |
|
A phase III, double-blind efficacy
and safety study of SCH 58235 in addition to lovastatin
compared to placebo in subjects with primary hypercholesterolemia. Sponsor: Schering-Plough, Sub-investigator,
Northeast Iowa Family Practice Center, 2000. |
|
| Research Interests |
|
Cardiovascular pharmacotherapy |
|
Hormonal replacement therapy |
|
Sedatives/hypnotics |
|
James
Hoehns , Pharm.D. 